Literature DB >> 19805003

Novel strategies for reversing platinum resistance.

Mian M K Shahzad1, Gabriel Lopez-Berestein, Anil K Sood.   

Abstract

Platinum-based drugs continue to be the mainstay of therapy for ovarian cancer. Along with adverse effects, chemoresistance (intrinsic or acquired) has become a major limitation in the management of recurrent disease. Even though much is known about the effects of platinum drugs on cancer cells, the mechanisms underlying resistance are poorly understood. In this review, we summarize the current data on chemoresistance and discuss novel strategies to reverse resistance to platinum-based drugs. The most important targets highlighted here include Aurora kinases, PARP, ATP7B, and ERCC1. Furthermore, we discuss the implications of these novel approaches for ovarian cancer treatment.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19805003      PMCID： PMC2789192          DOI： 10.1016/j.drup.2009.09.001

Source DB:  PubMed          Journal:  Drug Resist Updat        ISSN： 1368-7646            Impact factor:   18.500


  76 in total

Review 1.  Function and regulation of human copper-transporting ATPases.

Authors:  Svetlana Lutsenko; Natalie L Barnes; Mee Y Bartee; Oleg Y Dmitriev
Journal:  Physiol Rev       Date:  2007-07       Impact factor: 37.312

Review 2.  Mechanisms of resistance to cisplatin and carboplatin.

Authors:  David J Stewart
Journal:  Crit Rev Oncol Hematol       Date:  2007-03-01       Impact factor: 6.312

3.  Functional interactions of Cu-ATPase ATP7B with cisplatin and the role of ATP7B in the resistance of cells to the drug.

Authors:  Karoline Leonhardt; Rolf Gebhardt; Joachim Mössner; Svetlana Lutsenko; Dominik Huster
Journal:  J Biol Chem       Date:  2009-01-13       Impact factor: 5.157

4.  Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin.

Authors:  Trevor Hay; James R Matthews; Lucie Pietzka; Alan Lau; Aaron Cranston; Anders O H Nygren; Anthony Douglas-Jones; Graeme C M Smith; Niall M B Martin; Mark O'Connor; Alan R Clarke
Journal:  Cancer Res       Date:  2009-04-21       Impact factor: 12.701

5.  Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance.

Authors:  Elizabeth M Swisher; Wataru Sakai; Beth Y Karlan; Kaitlyn Wurz; Nicole Urban; Toshiyasu Taniguchi
Journal:  Cancer Res       Date:  2008-04-15       Impact factor: 12.701

Review 6.  How do real tumors become resistant to cisplatin?

Authors:  Piet Borst; Sven Rottenberg; Jos Jonkers
Journal:  Cell Cycle       Date:  2008-03-17       Impact factor: 4.534

7.  High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.

Authors:  Sven Rottenberg; Janneke E Jaspers; Ariena Kersbergen; Eline van der Burg; Anders O H Nygren; Serge A L Zander; Patrick W B Derksen; Michiel de Bruin; John Zevenhoven; Alan Lau; Robert Boulter; Aaron Cranston; Mark J O'Connor; Niall M B Martin; Piet Borst; Jos Jonkers
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-29       Impact factor: 11.205

8.  Overexpression of the centrosomal protein Aurora-A kinase is associated with poor prognosis in epithelial ovarian cancer patients.

Authors:  Charles N Landen; Yvonne G Lin; Anand Immaneni; Michael T Deavers; William M Merritt; Whitney A Spannuth; Diane C Bodurka; David M Gershenson; William R Brinkley; Anil K Sood
Journal:  Clin Cancer Res       Date:  2007-07-15       Impact factor: 12.531

9.  Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers.

Authors:  Wataru Sakai; Elizabeth M Swisher; Beth Y Karlan; Mukesh K Agarwal; Jake Higgins; Cynthia Friedman; Emily Villegas; Céline Jacquemont; Daniel J Farrugia; Fergus J Couch; Nicole Urban; Toshiyasu Taniguchi
Journal:  Nature       Date:  2008-02-10       Impact factor: 49.962

10.  Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth.

Authors:  Yvonne G Lin; Anand Immaneni; William M Merritt; Lingegowda S Mangala; Seung Wook Kim; Mian M K Shahzad; Yvonne T M Tsang; Guillermo N Armaiz-Pena; Chunhua Lu; Aparna A Kamat; Liz Y Han; Whitney A Spannuth; Alpa M Nick; Charles N Landen; Kwong K Wong; Michael J Gray; Robert L Coleman; Diane C Bodurka; William R Brinkley; Anil K Sood
Journal:  Clin Cancer Res       Date:  2008-09-01       Impact factor: 12.531
View more
  24 in total

1.  The ATP7B genetic polymorphisms predict clinical outcome to platinum-based chemotherapy in lung cancer patients.

Authors:  Xiang-Ping Li; Ji-Ye Yin; Ying Wang; Hui He; Xi Li; Wei-Jing Gong; Juan Chen; Chen-Yue Qian; Yi Zheng; Fang Li; Tao Yin; Zhi-Cheng Gong; Bo-Ting Zhou; Yu Zhang; Ling Xiao; Hong-Hao Zhou; Zhao-Qian Liu
Journal:  Tumour Biol       Date:  2014-05-23

2.  Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer.

Authors:  Angela J Ziebarth; Somaira Nowsheen; Adam D Steg; Monjri M Shah; Ashwini A Katre; Zachary C Dobbin; Hee-Dong Han; Gabriel Lopez-Berestein; Anil K Sood; Michael Conner; Eddy S Yang; Charles N Landen
Journal:  Clin Cancer Res       Date:  2012-11-12       Impact factor: 12.531

3.  Photoimmunotherapy and irradiance modulation reduce chemotherapy cycles and toxicity in a murine model for ovarian carcinomatosis: perspective and results.

Authors:  Imran Rizvi; Tri A Dinh; Weiping Yu; Yuchiao Chang; Margaret E Sherwood; Tayyaba Hasan
Journal:  Isr J Chem       Date:  2012-09       Impact factor: 3.333

4.  Improvement of a predictive model in ovarian cancer patients submitted to platinum-based chemotherapy: implications of a GST activity profile.

Authors:  Deolinda Pereira; Joana Assis; Mónica Gomes; Augusto Nogueira; Rui Medeiros
Journal:  Eur J Clin Pharmacol       Date:  2016-01-23       Impact factor: 2.953

5.  Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies.

Authors:  Siqing Fu; Ming-Mo Hou; Jennifer Wheler; David Hong; Aung Naing; Apostolia Tsimberidou; Filip Janku; Ralph Zinner; Sarina Piha-Paul; Gerald Falchook; Macus Tien Kuo; Razelle Kurzrock
Journal:  Invest New Drugs       Date:  2013-12-05       Impact factor: 3.850

6.  Virtual screening and biological evaluation of inhibitors targeting the XPA-ERCC1 interaction.

Authors:  Khaled H Barakat; Lars P Jordheim; Rolando Perez-Pineiro; David Wishart; Charles Dumontet; Jack A Tuszynski
Journal:  PLoS One       Date:  2012-12-14       Impact factor: 3.240

7.  Fucoxanthin enhances cisplatin-induced cytotoxicity via NFκB-mediated pathway and downregulates DNA repair gene expression in human hepatoma HepG2 cells.

Authors:  Cheng-Ling Liu; Yun-Ping Lim; Miao-Lin Hu
Journal:  Mar Drugs       Date:  2013-01-08       Impact factor: 5.118

8.  Gene expression and pathway analysis of ovarian cancer cells selected for resistance to cisplatin, paclitaxel, or doxorubicin.

Authors:  Cheryl A Sherman-Baust; Kevin G Becker; William H Wood Iii; Yongqing Zhang; Patrice J Morin
Journal:  J Ovarian Res       Date:  2011-12-05       Impact factor: 4.234

9.  Developing central nervous system and vulnerability to platinum compounds.

Authors:  G Bernocchi; M G Bottone; V M Piccolini; V Dal Bo; G Santin; S A De Pascali; D Migoni; F P Fanizzi
Journal:  Chemother Res Pract       Date:  2011-02-15

10.  Secreted frizzled-related protein 4 expression is positively associated with responsiveness to cisplatin of ovarian cancer cell lines in vitro and with lower tumour grade in mucinous ovarian cancers.

Authors:  Uttara Saran; Frank Arfuso; Nikolajs Zeps; Arunasalam Dharmarajan
Journal:  BMC Cell Biol       Date:  2012-10-08       Impact factor: 4.241
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.